Every claim we hold, and how far we can stand behind it.
142 claims across 39 products. 30% are confirmed against the source text by the evidence gate; 39% come from a class with no vendor interest. Everything below is browsable, filterable, and available as JSON.
| Evidence class | Claims | Confirmed | What it can support |
|---|---|---|---|
| Peer-reviewed study | 19 | 5 | Independent review before publication. The only class that survives a sceptical committee unaided. |
| Regulatory filing | 4 | 0 | A statement made to a regulator, where being wrong has consequences. |
| Independent report | 32 | 9 | Analysis by someone with no stake in the sale. |
| Customer case | 4 | 3 | A real deployment, but selected and framed by someone with an interest. |
| Press release | 63 | 23 | The vendor's own announcement. Useful for dates and facts, not for outcomes. |
| Vendor page | 20 | 2 | Marketing copy. Establishes what is claimed, never that it is true. |
Showing 6 of 6 matching claims (142 in the full corpus) · 50% of this selection is confirmed · clear filters
Real-world performance evaluation of the Aidoc Medical Briefcase ICH Triage model across 101,944 non-contrast head CT examinations from 74,142 patients in a 17-facility academic health system (April 2023-April 2025) demonstrated 82.2% sensitivity, 97.6% specificity, and 96.6% accuracy for intracranial hemorrhage detection (npj Digital Medicine).
Provenance
- Claim ID
- clm_c0fa19558e3ea5d6059f
- Version
- 1
- Workflow
- Imaging & Diagnostic AI
- Dimension
- evidence strength
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://pmc.ncbi.nlm.nih.gov/articles/PMC12823562/
Deployed across nearly 2,000 U.S. hospitals covering 230M+ lives as of late 2025 (up from 1,000+ hospitals in 2024); ~$291.5M total funding at a $1.2B valuation
Provenance
- Claim ID
- clm_617210a5c36dbf4691c7
- Version
- 1
- Workflow
- Imaging & Diagnostic AI
- Dimension
- deployment traction
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://sacra.com/c/viz-ai/
Meta-analysis of six retrospective real-world studies encompassing 9,102 CTPA scans, all assessing the Aidoc or CINA-PE FDA-approved algorithms for acute pulmonary embolism detection, found pooled sensitivity of 93% (95% CI 88%-95%) and specificity of 98% (95% CI 93%-100%) (Cureus).
Provenance
- Claim ID
- clm_15d57030cdd4dbabf213
- Version
- 1
- Workflow
- Imaging & Diagnostic AI
- Dimension
- evidence strength
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://pmc.ncbi.nlm.nih.gov/articles/PMC12604435/
Received FDA 510(k) clearance and launched the next-generation HeartFlow Plaque Analysis platform in September 2025
Provenance
- Claim ID
- clm_29c575ae0472e53b405e
- Version
- 1
- Workflow
- Imaging & Diagnostic AI
- Dimension
- evidence strength
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://ir.heartflow.com/news-releases/news-release-details/heartflow-announces-fda-510k-clearance-and-launch-next
Completed an upsized IPO on Nasdaq (HTFL) raising ~$364.2M in gross proceeds at $19/share; shares began trading Aug 8, 2025
Provenance
- Claim ID
- clm_6d2284fb4d9b5d1ed5da
- Version
- 1
- Workflow
- Imaging & Diagnostic AI
- Dimension
- market durability
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://ir.heartflow.com/news-releases/news-release-details/heartflow-inc-announces-closing-upsized-initial-public-offering
CEO Prashant Warier states Qure.ai aims to reach profitability in the next financial year and pursue an IPO within roughly two years (May 2025)
Provenance
- Claim ID
- clm_feb6e7535e4e9cab9d13
- Version
- 1
- Workflow
- Imaging & Diagnostic AI
- Dimension
- market durability
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://m.economictimes.com/tech/artificial-intelligence/healthcare-ai-startup-qure-ai-aiming-for-ipo-in-two-years-ceo-says/articleshow/121286035.cms